Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumors, today announced that Dr. Cheng Liu, President and CEO, is scheduled to participate in person at the PEGS Boston Conference and Expo at Hynes Convention Center on May 2-6, 2022.

Dr. Liu will be participating in two engagements. He will be hosting a roundtable discussion on the challenges and opportunities of targeting intracellular antigens and presenting Eureka’s approach of using TCR-mimic antibodies to target intracellular antigens, both in the Oncology Stream - Antibodies for Cancer Therapy Track.

ABOUT EUREKA THERAPEUTICS, INC.

Eureka Therapeutics, Inc. is a privately-held clinical-stage biotechnology company focused on developing novel T-cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS^® cell receptor platform and E-ALPHA^® antibody discovery platform for the discovery and development of potentially safer and more effective T-cell therapies for the treatment of solid tumors and hematologic malignancies. The company currently has two clinical programs, ET140203 (ARYA1 and ARYA2) and ECT204 (ARYA3), in Phase I/II US trials in patients with advanced liver cancer.

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005274/en/

Meet @EurekaThera’s President and CEO, Dr. Cheng Liu @PEGSboston Conference & Expo, May 2-6, where he will be sharing his insights on targeting intracellular antigens with #TCR-mimic #antibodies in the Antibodies for Cancer Therapy Track.